EORTC studies opened since 15 December 2010

23/02/2011

EORTC trial 26081 – 22086

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with Newly Diagnosed Anaplastic Oligodendroglioma or Anaplastic Mixed Glioma with Chromosomal Co-delections of 1p and 19q

Target Accrual: 544 patients

Study Coordinators:

  • Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam
  • Frederic Dhermain – Institut Gustave Roussy, Villejuif
  • Wolfgang Wick – Universitaetsklinikum Heidelberg – Kopfklinik, Heidelberg

EORTC trial 10085

Clinical and biological characterization of Male Breast Cancer: an international retrospective EORTC, BIG and NABCG intergroup study

Target Accrual: 1800 patients

Study Coordinator:

  • Fatima Cardoso – Institut Jules Bordet – Brussels

EORTC trial 26091

Randomized trial assessing the significance of Bevacizumab in recurrent grade II and grade III gliomas

Target Accrual: 144 patients

Study Coordinators:

  • Martin van den Bent – Erasmus University Medical Center, Rotterdam
  • Ahmed Idbaih – CHU Pitié-Salpêtrière, Paris

EORTC studies to be opened in 2011 (in regulatory process)

EORTC trial 58081

Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL)

Target Accrual: This trial is a prospective observational – biobanking study.

Study Coordinators:

  • Helene Cave, Hôpital Robert Debre (AP-HP), Paris
  • Yves Benoit, Universiteit Gent, Gent

EORTC trial 22071-24071

Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence

Target Accrual: 800 patients for the main study, 150 patients for the pre-study

Study Coordinators:

  • Wilfried Budach – Heinrich-Heine Universitaetsklinik Dusseldorf, Duesseldorf
  • Johannes Langendijk – University Medical Center Groningen, Groningen
  • Carla Van Herpen – Radboud University Nijmegen Medical Center, Nijmegen

EORTC trial 62091

A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma

Target Accrual: 340 patients

Study Coordinator:

  • Binh Bui-Nguyen – Institut Bergonie, Bordeaux

EORTC trial 26101

Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma

Target Accrual: 249 patients

Study Coordinator:

  • Wolfgang Wick – UniversitaetsKlinikum Heidelberg – Kopfklinik, Heidelberg

EORTC trial 58LAE (Late Adverse Events)

Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998

Target Accrual: 3138 patients

Study Coordinator:

  • Caroline Piette – Centre Hospitalier Regional De La Citadelle, Liege

EORTC trial 65091-06093

Empirical versus pre-emptive antifungal therapy in patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups

Target Accrual: 556 patients

Study Coordinator:

  • Peter Donnelly – Radboud University Nijmegen Medical Centre, Nijmegen

EORTC trial 06083 HOVON 100 ALL

Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial

Target Accrual:  – patients

Study Coordinator:

  • Jean-Pierre Marie – Hopital Saint Antoine AP-HP, Paris

EORTC trial 08092 MAPPING

Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy

Target Accrual:  587 patients

Study Coordinator:

  • Mary O’Brien – Royal Marsden Hospital, Sutton

 

 John Bean

Facebooktwitterlinkedinmail

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200
Belgium

Contact us

Follow us

Funding